Tazverik Accelerated Approval: Disease Rarity And Unmet Need Won Out Over Efficacy Concerns

 
• By Sue Sutter
  
Drug Review Profile regular column
US FDA exercised regulatory flexibility with the accelerated approval of Tazverik.
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Drug Review Profiles

More from Product Reviews